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PhospholipidPegylation of nanoparticles has been widely implemented in the ﬁeld of drug delivery to prevent macrophage
clearance and increase drug accumulation at a target site. However, the shielding effect of polyethylene glycol
(PEG) is usually incomplete and transient, due to loss of nanoparticle integrity upon systemic injection. Here,
we have synthesized unique PEG-dendron-phospholipid constructs that form super stealth liposomes (SSLs). A
β-glutamic acid dendron anchor was used to attach a PEG chain to several distearoyl phosphoethanolamine
lipids, thereby differing from conventional stealth liposomes where a PEG chain is attached to a single phospho-
lipid. This composition was shown to increase liposomal stability, prolong the circulation half-life, improve the
biodistribution proﬁle and enhance the anticancer potency of a drug payload (doxorubicin hydrochloride).
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Nanodelivery systems have been designed for the treatment of vari-
ous diseases, such as cancer, diabetes, infections, allergy, asthma, andneu-
rological disorders [1,2]. Indeed, nano-sized carriers have the potential to
improve biopharmaceutical features, pharmacokinetic properties and the
therapeutic efﬁcacy of entrapped drugs [3]. A broad range of materials
have been used for the fabrication of nanocarriers, including silicon and
silica [4,5], lipids [6–8], polymers [9], surfactants [10,11], and metal [12].
Currently, there are several nanotherapeutics that are in clinical trials or
have received approval, many of which are liposomal drugs [13,14]. The
ﬁrst liposomal formulation, Doxil, was approved by the Food and Drug
Administration (FDA) in 1995 for the treatment of AIDS associated with
Kaposi's sarcoma [15]. Since then, 14 liposomal drugs havebeen approved
and 21 are enrolled in clinical trials [16–18]. Among these formulations
several are approved for the treatment of cancer, includingDepoCyt (lipo-
somal cytarabine), DaunoXome (liposomal daunorubicin), Myocet (lipo-
somal doxorubicin, approved in Europe and Canada), Doxil/Caelyxcia" of Catanzaro, Building of
ta”, I-88100 Germaneto, Italy.
. This is an open access article under(liposomal doxorubicin), Sarcodoxome (liposomal doxorubicin),Marqibo
(liposomal vincristine), and Lipusu (liposomal paclitaxel, approved in
China) [18,19].
In order to improve the properties of liposomes and other drug de-
livery vehicles, polymers can be incorporated into these formulations
[20,21]. This practice has opened up new opportunities in the ﬁeld of
pharmaceutical research and the design of novel polymer-based nano-
particles has been reported extensively in the literature [22–27]. Poly-
ethylene glycol (PEG) is the most commonly used polymer in clinical
practice [28]. Themethoxy formof PEG, usually used for conjugation ap-
plications, has a single hydroxyl group that can be coupled with several
entities, including small drugs, proteins, polymers and lipids [20]. Con-
sequently, pegylation results in stealth shielding and increased circula-
tion times [29]. In particular, the stealth effect is due to the formation of
a dense hydrophilic barrier of PEG chains on the surface of the carrier,
thereby reducing interactions with the reticular-endothelial system
(RES). In addition, pegylation increases the hydrodynamic size of drug
delivery systems and consequently decreases their clearance from the
body [30,31]. Together these factors illustrate that the incorporation of
PEG can improve the performance of nanovesicles. However, it should
be noted that some forms of PEG-phospholipids might cause activation
of the complement system and potentially cause pseudoallergic reac-
tions [32].the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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speciﬁc PEG-phospholipids, such as methoxy-PEG-distearoyl
phosphoethanolamine (mPEG-DSPE), which can interact with the
phospholipid bilayer through hydrophobic interactions. Liposomes
surrounded by PEG chains are called stealth liposomes (SLs), as they
are able to escape macrophage uptake [28,33]. Although this strategy
increases the in vivo half-life of drug delivery systems [28], the beneﬁ-
cial effect of PEG shielding is limited. The limitation is due to the detach-
ment of mPEG-phospholipid molecules from the surface of liposomes.
This decrease in stability occurs when plasma proteins in the blood
interact to the surface of nanoparticles, thereby, simultaneously modi-
fying the distribution of PEG chains surrounding the surface of lipo-
somes [34]. An additional limitation of stealth liposomes is the
incomplete PEG shielding of the surface, leaving the carrier vulnerable
to opsonization [35]. In this study, we have used novel PEG-dendron-
phospholipids in order to create stable carrier systems, which we have
termed super stealth liposomes (SSLs). The dendron structure acts as
an anchor that enables several phospholipids to bind to a single PEG
chain. This set-up enhances the interaction strength between mPEG-
phospholipids and the phospholipid bilayer, thereby creating liposomes
with higher stability. Throughout this studywe have compared the per-
formance of the SSLs to that of a conventional SL.
2. Materials and methods
2.1. Synthesis and characterization of mPEG-dendron derivates
PEG-dendron derivates were synthesized by conjugating mPEG-OH
5 kDa with nor-leucine (NLeu) or β-glutamic acid (βGlu) and further
conjugating with DSPE. A pNO2-phenyl activated PEG carbonate was
prepared and puriﬁed by precipitation from diethyl ether and conjuga-
tion to NLeu or βGlu was performed in a borate buffer solution with a
pH of 8. The intermediate, mPEG-NLeu-COOH or mPEG-βGlu, was ex-
tracted from the acidiﬁed solution with dichloromethane, concentrated
to obtain a small volume, and recovered by precipitation in diethyl
ether. The activation of these derivatives was carried out according to
the standard procedure involving dicychlohexylcarbodiimide (DCC),
and N-hydroxysuccinimide (NHS). For the synthesis of mPEG-
βGlu(βGlu)2(DSPE)4, the reactions of βGlu coupling and activation via
DCC/NHS was performed. The activated mPEG-NLeu-NHS, mPEG-
βGlu(NHS)2 or mPEG-βGlu(βGlu)2(NHS)4 was added to a DSPE chloro-
form solution and left to react overnight at 45 °C. The solvent was then
removed under vacuumand the residue dissolved inwater and dialysed
against 50 mM NaCl and then against water using a membrane with a
molecular cut-off of 100 kDa. The derivatives were recovered by
freeze-drying. A further puriﬁcation of mPEG-dendron derivates was
carried out by dissolving the products in chloroform with equimolar
amounts of stearoil chloride and triethylammine. The obtained reaction
mixture was dropped into diethyl ether and the ﬁnal products were re-
covered by ﬁltration and dried under vacuum. The derivatives were
characterized by 1H-NMR spectroscopy and the Snyder assay [36].
2.2. Preparation of the SL and SSLs
The lipid composition for the SL was DPPC:Chol:mPEG2000-DSPE in
a 6:3:0.5 molar ratio. In SSL(1) the PEG200-DSPE was interchanged for
mPEG-NLeu-DSPE, in SSL(2) for mPEG-βGlu(DSPE)2 and in SSL(4) for
mPEG-βGlu(βGlu)2(DSPE)4. The lipids were dissolved in a round-
bottom ﬂask with 2 ml of a chloroform/methanol solution and the or-
ganic solvent was evaporated using a Rotavapor®. The liposomes
were loaded with Dox through the use of a pH gradient remote loading
procedure, as previously reported [37]. The SL and SSL formulations
were then extruded through a stainless-steel extrusion device using
polycarbonate membrane ﬁlters with 400 nm, 200 nm and 100 nm
pores. Fluorescein DHPE (0.1% molar concentration) or 3H[CHE]
(1.25 μCi per formulation) were separately co-dissolved into lipidmaterials during the preparation procedure in order to obtain
ﬂuorescent- and 3H[CHE]-mPEG-SSLs, respectively.
2.3. Puriﬁcation and drug entrapment efﬁciency
Ultracentrifugation and gel ﬁltration chromatography (GFC) were
carried out in order to purify the SL and SSLs (from unstructured
mPEG-dendron phospholipids and unentrapped drug) and to evaluate
the drug entrapment efﬁciency. To avoid the dilution effect arising
from the GFC puriﬁcation procedure an ultracentrifugation method
was also performed to further purify the formulations before in vitro
and in vivo experiments. The amount of Dox entrapped within the SL
and SSLs was evaluated according to a mathematical equation reported
in the Supplementary material section.
2.4. Physicochemical characterization of the SL and SSLs
Dynamic light scattering was carried out to evaluate the physico-
chemical properties of the SL and SSLs [38]. Mean size, size distribution
and zeta potential were evaluated using a Zetasizer Nano ZS apparatus
(Malvern Instruments Ltd., Worchestershire, United Kingdom).
2.5. Evaluation of liposome stability by ITC and DLS
A conventional liposome, the SL and SSLswere subjected to TritonX-
100 titration and monitored with ITC on a VP-ITC titration calorimeter
(GE Healthcare, Uppsala, Sweden) [39] and by DLS. The titrant concen-
tration at the solubilization boundary (CD)was used to compare the sta-
bility of the vesicles. Further details about the stability measurements
can be found in the Supplementary material section.
2.6. Fusion assays
FRET analysis was performed to evaluate vesicle fusion. A conven-
tional liposome, the SL, and SSLs were formulated using energy donor
and acceptor ﬂuorescent probes prepared and co-incubated at 25 °C
with a three-fold excess of unlabeled liposomes. CaCl2 was added to
the liposomalmixture to reach a ﬁnal concentration of 10mM. Theﬂuo-
rescence emission of the energy donor probe was measured using a
spectroﬂuorometer (PerkinElmer LS-55, PerkinElmer, Monza (MB),
Italy). A more detailed description of FRET analysis can be found in the
Supplementary material section.
2.7. In vitro intracellular accumulation of Dox
CaCo-2 cells (1.5 × 105/ml) were seeded in a 24-well plate and incu-
bated at 37 °C with 5% CO2. After 24 h of incubation, cells were treated
with free Dox, Dox/SL or Dox/SSLs (0.5 μM Dox) for various time pe-
riods. Cells were then washed with cold PBS buffer and lysed in 100 μl
lysis buffer. The concentration of Dox was measured using a ﬂuores-
cence spectrophotometer at 480 nm (λExcitation) and 575 nm (λEmission).
The standard curve consisted of cellular lysates with scalar dilutions of
Dox. The drug concentration was correlated to the amount of protein
in the lysates. More details about the intracellular drug concentration
measurements can be found in the Supporting material section.
2.8. Release proﬁle of Dox from the SL and SSLs
The release of Dox from the SL and SSLs was investigated using a
ﬂuorescence dequenching assay according to a protocol reported in
the Supplementary material section [40].
2.9. RP-HPLC method for Dox quantiﬁcation
An HPLC apparatus was used to quantify the amount of Dox. The
chromatographic separation was carried out using a reverse phase C18
Fig. 1. Synthesis of pegylated dendron phospholipids for self-assembly of the stealth liposome (SL) and super stealth liposomes (SSLs) for anticancer therapy. a, The chemical structure of
dendron phospholipids. b, Preparation procedure of SSLs. The formulations are prepared by using the following procedures: Thin layer evaporation, use of an ammonium sulfate pH gra-
dient (250 mM) and extrusion through polycarbonate ﬁlter membranes (400 nm, 200 nm and 100 nm pores) (see the Materials and methods and Supplementary materials sections). c,
Schematic representation of the SL and SSLs. In the SSLs the pegylated dendron derivates are attached tomultiple lipid units. For clarity purposes the PEG chains have been depicted on the
outer liposomal membrane. However, in reality, the chains are also present on the innermembrane. βGlu, β-glutamic acid; DSPE, distearoyl phosphoethanolamine; mPEG, methoxy poly-
ethylene glycol; NLeu, Nor-leucin.
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water and acetonitrile (25:75 v/v). The ﬂow rate was 1.0 ml/min and
the UV/Vis detector was set at 480 nm. An external calibration curve
was used to quantify the samples. RP-HPLC was also used for the phar-
macokinetic quantiﬁcation of Dox. Chromatograms were acquired after
drug extraction from plasma samples and interference between the
drug and plasmatic protein was not observed.Fig. 2. Triton X-100 destabilization of liposomes. Evaluation of the stability of a conventional lip
scattering (DLS) (b). a, The integrated and normalized heat of reaction (Q) as a function of total
equivalent) vesicle formulation with a 45mMTriton X-100 solution. b, Vesicle size obtained by
The data is reported as the mean of three different experiments ± standard deviation.2.10. Pharmacokinetic investigations
The Ethic Committee of the University of Padua approved the experi-
ments (CEASA 24/2013) and all animals received care according to the
DLGS 116/92 and in compliance with the “Guide for the Care and Use of
Laboratory Animals”. BALB/c mice (7–8 week old, 24–28 g) were used
for the pharmacokinetic experiments. The mice received tail veinosome (Lip), SL and SSLs using isothermal titration calorimetry (ITC) (a) and dynamic light
detergent concentration in the ITC sample cell (CD) was obtained by titrating a 3mM (lipid
titrating a 3mM (lipid equivalent) vesicle formulationwith a 5mM Triton X-100 solution.
Fig. 3. Physicochemical characterization of SSL(4) self-assembled frommPEG-βGlu(βGlu)2(DSPE)4. a, Schematic representation of SSL(4) (mPEG-βGlu(βGlu)2(DSPE)4). b, Release proﬁle of
Dox from pegylated liposomes determined using a ﬂuorescence dequenchingmethod. The results are expressed as the± standard deviation of three samples. Error bars, if not visible, are
concealed behind the symbols.
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phate buffer solution at a pH of 7.4 (60 μg of Dox). At scheduled time
points blood samples (~150 μl) were collected from the retro-orbital ve-
nous plexus by using heparin treated tubes and thereafter immediately
centrifuged. A daunomicin solution was used as an internal standard.
The samples were quantiﬁed by HPLC as reported elsewhere [41]. The
data was analyzed by applying a two compartments model using the
PKSolver program.
2.11. Biodistribution of the SL and SSLs
Biodistribution analysis was carried out in BALB/c mice (7–8 week
old, 24–28 g). Mice were divided into four groups and injected through
the tail vein with 3H[CHE]-SL/SSLs (200 μl, 0.5 μCi of 3H[CHE]). At differ-
ent time points (1, 8, 16 and 24 h) blood was collected from the retro-
orbital plexus and mice were then sacriﬁced. The heart, lungs, liver,
spleen and kidneys were surgically harvested and the tissue weights
were recorded (Table S2). The organs and blood were digested with a
quaternary ammonium hydroxide solution, acidiﬁed with sulfuric acid
(1 N) and quantiﬁed using a β scintillation counter. The biodistribution
was expressed as the percentage of injected dose per gram of tissue.Fig. 4. Confocal laser scanningmicrographs of CaCo-2 cells incubatedwith ﬂuorescein labeled SL
time periods (1 h, 6 h, 12 h and 24 h). a, SL. b, SSL(1). c, SSL(2). d, SSL(4). e, Control (untreated C2.12. Stability of 3H[CHE]-SL/SSL in serum
3H[CHE]-SL/SSLs were used to evaluate the liposomal stability. Li-
posomes diluted in PBS buffer solution (500 μl, pH 7.4) were incubat-
ed with bovine serum (500 μl). The samples were maintained under
continuous stirring at 37 °C and 50 μl of solution was withdrawn at
different time points. The collected solutions were spun down with
Bio-Gel A-15 spin columns and analyzed using a β-scintillation
counter.2.13. In vitro anticancer activity
The anticancer activity of the free drug andDox-SL/SSLswas assayed
in CaCo-2 cells using the MTT viability test. Different doses and incuba-
tion times were evaluated. Cells were treated with 200 μl of freshmedi-
um (control), empty SSLs (blank control) or different concentrations of
free drug and Dox-SL/SSLs. The anticancer activity (cell viability per-
centage) was evaluated after 24 h, 48 h or 72 h of incubation and quan-
tiﬁed with a UV spectrophotometer micro plate reader and the
absorption was measured at a wavelength of 570 nm.and SSLs. CaCo-2 cells were treatedwith ﬂuorescent SL or SSLs and incubated for different
aCo-2 cells).
Fig. 5. In vitro dose-dependent antitumor effects of free doxorubicin hydrochloride (Dox)
and Dox loaded SL and SSL(4) in CaCo-2 cells. a, 24 h incubation. b, 48 h incubation. c, 72 h
incubation. Legend symbols: Free Dox (●); Dox-SL (▼), Dox-SSL(4) (■). Untreated cells
were used as controls (100% viability). The results are expressed as the average of three
different experiments ± standard deviation. Error bars, if not visible, are concealed
under the symbols.
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CLSM was carried out on CaCo-2 cells by using ﬂuorescein-DHPE as
a labeling agent. Cells were seeded in 6-well plates with glass slides
(6.0 × 104 cells/ml) and incubated for 24 h. The cells were then treated
with ﬂuorescent SL and SSLs and incubated for different time periods
(1 h, 3 h, 6 h, 12 h and 24 h). At the end of the incubation period excess
ﬂuorescein-labeled vesicles were removed with PBS buffer solution
(pH 7.4) and cells were ﬁxed with cooled ethanol solution. Excess etha-
nol was removed and the cells were further washed with PBS buffer so-
lution (pH 7.4). 200 μl of cellular suspension was loaded onto a glass
holder and ﬁxed with a 95% (v/v) ethanol solution. Quantiﬁcation was
performedwith a Leica TCS SP2MP confocal laser scanningmicroscopy.
3. Results and discussion
3.1. Design, preparation and physicochemical characterization of SSLs
We have designed a series of mPEG-dendron-phospholipid deriva-
tives that have been synthesized in-house. The hydroxyl end of an
mPEG chain was attached to a dendron anchor, consisting of N leucin
(NLeu), β-glutamic acid (βGlu) or βGlu(βGlu)2. At the opposite side
the anchor was conjugated to one, two or four DSPE units, resulting in
the following constructs: SSL(1) (mPEG-NLeu(DSPE)), SSL(2) (mPEG-
βGlu(DSPE)2) and SSL(4) (mPEG-βGlu(βGlu)2(DSPE)4) (Fig. 1a). 1H-
NMR spectroscopy was used to conﬁrm the ratio between the polymer
and the DSPE lipids (Supplementary Fig. S1). Measurements at the crit-
ical concentration for aggregation (CCA) show that the dimensions of
the lipid derivatives remain small (Supplementary Fig. S2). This result
demonstrates the lack of aggregates or micelles, which increases the
chance that the lipid derivatives will be successfully integrated within
the phospholipid bilayer. The dendron structures were then self-
assembled with other lipid components to obtain SSLs. The mean size
of the SSLs was ~160 nm and the narrow size distribution was below
0.2 (Supplementary Table S1). All SSLs, except SSL(1), had a greater neg-
ative zeta potential value than that of PEGylated liposomes (Supple-
mentary Table S1). This ﬁnding was expected as SSL(1) derivatives
only have one lipid unit attached to the PEG chain, resembling conven-
tional PEGylated liposomes. The zeta potential data was measured as a
function of electrophoretic mobility (Supplementary Table S1).
The SSLs were further analyzed using a PEG enzyme-linked immu-
nosorbent assay (ELISA) kit to evaluate potential differences in the con-
centration of PEG on the vesicular surface. The order from highest to
lowest PEG content was the following: SSL(4) N SSL(2) N SL (Supplemen-
tary Fig. S3). Higher amounts of PEG on the surface of SSL(4) may be at-
tributable to the βGlu(βGlu)2 spacer, which strongly anchors the PEG
moieties to four phospholipid units.
Isothermal titration calorimetry (ITC) and dynamic light scattering
(DLS) experiments were performed to evaluate the stability of a con-
ventional liposome (Lip), a SL and SSLs exposed to Triton X-100 titra-
tion. ITC demonstrated that the QD (kcal/mol) values drop abruptly at
the solubilization boundary, which separates the bilayer/micelle coexis-
tence range from the micelle range (Fig. 2a). The order of stability from
the highest to the lowest was the following: SSL4 N SSL2 N SL N Lip. The
same order of stability was observed when the titration was performed
in conjunction with DLS, which measures the size of colloidal vesicles
(Fig. 2b). In particular, at higher concentrations of Triton-X 100, the
size of SSL(4) increased, while the other liposomes were disrupted.
This observation indicates that despite the change in size, SSL(4) is able
to withstand the intercalation of surfactant into the lipid bilayer. The
evaluation of the polydispersity index (PDI) as a function of the Triton
X-100 concentration revealed that SSL(4) displayed an abrupt increase
in PDI (N0.4) at a higher surfactant concentration as compared to the
other liposomes (Supplementary Fig. S4), providing further evidence
that SSL(4) exhibits improved stability. When comparing ITC and DLS,
slight differences were observed in the detergent concentration (CD)that was required for solubilization. This discrepancy may be ascribed
to the use of different protocols, e.g. continuous mixing during ITC and
varying time intervals between detergent additions. Fluorescence reso-
nance energy transfer (FRET) analysis was performed to measure lipo-
somal fusion, which is an indication of liposomal instability. The
results suggest that the conventional liposome underwent fusion,
while the structural integrity of the stealth liposome and the super
stealth liposomes was maintained (Supplementary Fig. S5). The SSL(4)
and SSL(2) displayed slightly higher stability compared to the SL (Sup-
plementary Fig. S5).
The SSLswere evaluated as anticancer drug carriers (Fig. 1b,c) by en-
capsulating doxorubicin hydrochloride (Dox) in the liposomal core. All
Table 1
Main pharmacokinetic parameters of free Dox, the SL and SSLs after intravenous injection
in Balb/C mice (50–60 days old, 24–28 g).
Formulations t½ α
(min)a
t½ β
(min)b
AUC 0–∞
(μg/ml·min)
Vss
(ml)
Cl
(ml/min)c
Free Doxd 2.7 154.2 7.3 1740.3 83.7
Doxd-SL 4.7 151.6 2705.8 4.3 0.103
Doxd-SSL(1) 3.92 144.5 2403.1 4.0 0.102
Doxd-SSL(2) 8.97 633.5 7063.8 7.5 0.113
Doxd-SSL(4) 29.0 888.3 20424.5 3.4 0.016
a Distribution half-life.
b Post-distribution half-life.
c Cumulative clearance.
d Doxorubicin hydrochloride.
Fig. 6. Intracellular accumulation of free DOX, DOX-SL, DOX-SSL(2), DOX-SSL(4) in CaCo-2
cells. The experiments were carried out at 37 °C at a drug concentration of 0.5 μM. Each
bar represents the average value of three different experiments + standard deviation.
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suitable for systemic administration and drug delivery (Fig. 3 a,c and
Supplementary Table S1). In particular, the small size allows the carrier
to move through endothelial fenestrations (~200 nm) in neo-formed
tumor vasculature [42]. The mean size of the Dox-SSLs was similar to
that of empty SSLs (~160) (Fig. 3a,b), with the exception of SSL(4)
(~189 nm) (Supplementary Table S1). The zeta potential values also
remained unchanged after the addition of Dox (Supplementary
Table S1). In all of the SSLs the entrapment efﬁciency of Dox was higher
than 80% (Supplementary Fig. S6). Indeed, the presence of a trans-
membrane pH gradient promoted the arrangement of the drug into
the aqueous compartment, forming a gel-like structure and avoiding
leakage from the vesicular bilayer [43]. All liposomal formulations
displayed a slow release of Dox, i.e. lower than 0.5% after 2 h ofFig. 7. Serum incubation of SL and SSLs. a, Schematic description of the effect of serumproteins o
3[H]CHE from the SL and SSLs was used as a measurement for stability. Legend symbols: SL (●
periments ± standard deviation. Error bars, if not visible, are concealed under the symbols.incubation (Fig. 3b). This ﬁnding is in agreementwith previous observa-
tions of conventional liposomes (Lip) and SL [43].
3.2. In vitro and in vivo investigations of SSLs
The internalization of liposomes in CaCo-2 cells was evaluated by in-
cluding a ﬂuorescein-conjugated lipid in the liposomal bilayer. The re-
sults show that SSLs accumulate in higher amounts inside the cells, in
comparison to the SL (Fig. 4).
Although hydrophilic polymers are known to decrease the interac-
tions between liposomes and biological substrates, other factors should
also be considered in order to explain the improved intracellular uptake
of SSLs. Firstly, interactions between liposomes and cells also depend on
the physicochemical features and lipid compositions of vesicles [44], e.g.
negatively charged liposomes have increased cellular uptake in vitro
and in vivo in comparison to neutral liposomes [45,46]. Thus, the in-
creased cellular internalization could be attributable to the fact that
SSLs are more anionic than SL (Supplementary Table S1). Secondly,
the improved intracellular uptake of SSLsmay be due to interactions be-
tween the dendron anchors and the cell membrane. For instance, it is
possible that some of the glutamic acid dendron derivatives are able
to interact with glutamate receptors on the surface of cancer cells,
thereby triggering internalization. Thirdly, vesicle size also plays a rolen lipid detachment from the liposomal bilayer. b, Stability of SSLs in serum. The leakage of
), SSL(1) (▼); SSL(2) (■) and SSL(4) (♦). The results are the average of three different ex-
Fig. 8. Biodistribution of 3[H]CHE-labeled SL and SSL(4) after intravenous injection in Balb/C mice. 3[H]CHE-labeled SL and SSL(4) (200 μl, 0.5 μCi of 3[H]CHE) was injected through the tail
vein and quantiﬁed at different incubation times (1, 8, 16 and 24 h). Bloodwas collected andmicewere sacriﬁced. The amount of liposomes in the blood and liver was determined a, SL. b,
SSL(4). Results are the average of three experiments ± standard deviation. ID, injected dose.
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the sizes of SSLs differed slightly from that of SL, potentially affecting in-
tracellular uptake (Supplementary Table S1). As can be seen in Fig. 4,
SSL(4) displayed lower intracellular uptake in comparison to SSL(1) and
SSL(2). This effect may be dependent on the conformation of PEG, i.e. it
is possible that the PEG chains on SSL(4) are in a brush conformation,
which partially prevents endocytosis [48].
Safety and biocompatibility of mPEG-dendron derivates alone or
self-assembled into SSLs were tested using human keratinocyte cells
(NCTC 2544), as previously reported in the literature [49]. The cells
that were incubated with the dendron structures had a viability of
over 90% after 72 h (Supplementary Fig. S7) and showed normal mor-
phology (Supplementary Fig. S8). Cells subjected to drug-free SSLs
also showed high cell viability, which was similar to that of the empty
SL (Supplementary Fig. S9).
The Dox-SSLs were tested in CaCo-2 cells to evaluate the anticancer
activity and the efﬁcacy was compared to that of Dox-SL and free Dox.
Dose-dependent and time-dependent experiments were performed
(Fig. 5 and Supplementary Figure S10). When Dox was loaded into
SSL(4) and SSL(2) it showed higher toxicity (~57 % and ~59 % cell viabil-
ity) than when loaded into the SL (~92%) or when used as a free drug
(~94%) (0.01 μM, 72 h) (Fig. 5 and Supplementary Fig. S10). At the low-
est Dox concentration (0.01 μM) only SSL(4) showed a signiﬁcant reduc-
tion in cell viability (~77%, 24 h and 48 h) (Supplementary Fig. S10a,b).
In order to achieve a similar reduction of cell viability with the SL or the
free drug a 1000-fold higher dose of drug was needed (Supplementary
Fig. S10a). The intracellular uptake of Dox, Dox-SL, Dox-SSL(2) and
Dox-SSL(4) was measured in CaCo-2 cells. The levels of intracellular
Dox were higher when using SSL(2) and SSL(4) in comparison to SL and
native drug (Fig. 6).
Since theproperties of liposomes can change considerably in an in vivo
environment [50], the stability of SSLs was evaluated in serum. In partic-
ular, the integrity of liposomeswasmeasured by including 3H[CHE] in the
bilayer. The release of 3[H]CHE can be used as an indirectmeasurement of
liposome stability, since it is a nonexchangeable lipid marker. In fact, 3[H]
CHE cannot be released from the lipid bilayerwithoutmodifying the lipo-
some structure, which typically entails the detachment of phospholipids.
The results show that there is a large difference in the stability of SL and
SSL(1) in comparison to SSL(2) and SSL(4) (Fig. 7a,b). After 180 h SL and
SSL(1) had ~130 μCi 3H[CHE] per μg serum, while SSL(2) and SSL(4) had
~10 μCi 3H[CHE] per μg serum (Fig. 7b).
Furthermore, SSL(2) and SSL(4) in comparison to SL and SSL(1), signif-
icantly improved the biopharmaceutical features and pharmacokinetic
proﬁle of Dox after in vivo injection (Supplementary Fig. S11 and S12
and Table 1). Especially SSL(4) showed a 6.2-fold increase in thedistribu-
tion half life (t½ α) and 5.86-fold increase in the post-distribution halflife (t½ β) of Dox, respectively and a 7.6-fold increase in the area
under the plasma concentration–time curve (AUC) value in comparison
to SL (Supplementary Fig. S12 and Table 1). This supports the in vitro
ﬁndings and suggests that the stability of SSLs is also greater than that
of SL in an in vivo environment. Moreover the biodistribution of SL
and SSLs was measured in a time dependent manner (1, 8, 16 and
24 h after i.v. administration) in six different organs, including the circu-
latory system. We show that SSLs are present in the blood in greater
amounts and for longer times and accumulate at a lower extent in the
RES (Fig. 8a,b and Supplementary Fig. S11 a,b). After 1 h the percentage
of injected dose (ID) per gram of tissue in the liver was ~44% with SL vs
~9%with SSL(4), while the values for the bloodwere 9%with SL and 30%
with SSL(4) (Fig. 8).
4. Conclusions
The following study proposes the use of mPEG-dendron-
phospholipids to improve biopharmaceutical and pharmacokinetic fea-
tures of liposomes.We have synthesized novel mPEG derivates that self
assemble into super stealth liposomes. The dendron structure results in
an increase of the phospholipid/PEG attachment ratio and consequently
ensures amore stable interaction between the PEG chains and the vesic-
ular surface. The stable interaction inhibits the rapid detachment of PEG
in the circulatory system. Indeed, Triton X-100 titration showed that the
SSLs were more resistant to solubilization by a surfactant. Likewise, the
SSLs demonstrated less detachment of lipids from the liposomal bilayer
in the presence of serum proteins. The pharmacokinetic proﬁle of SSLs,
particularly SSL(4), exceeds that of conventional PEGylated liposomes.
SSLs have increased stability, prolonged circulation half-life, and lower
uptake in RES organs in comparison to the stealth liposome. Further-
more, in vitro studies suggest that SSLs have low toxicity and high intra-
cellular uptake. Cell culture studies also demonstrate that Dox loaded
within an SSL outperforms both Dox-SL and free Dox. Notably, the
Dox dose usedwith SSLs can be up to 1000-fold lower than convention-
al stealth liposomes to achieve the same anticancer activity in vitro. The
reason for the improved therapeutic efﬁcacy could be a combination of
increased intracellular uptake and drug release of SSLs. The obtained re-
sults demonstrate that SSLs may have the potential to greatly improve
conventional cancer treatment by enhancing drug delivery and antitu-
mor efﬁcacy.
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